NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, October 25th. Investors of record on Wednesday, November 13th will be given a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.54%. The ex-dividend date is Tuesday, November 12th. View Allergan's Dividend History.

Allergan announced that its board has initiated a stock buyback plan on Tuesday, January 29th 2019, which allows the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 4.1% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's management believes its shares are undervalued.

Allergan plc (NYSE:AGN) issued its quarterly earnings results on Tuesday, November, 5th. The company reported $4.25 EPS for the quarter, hitting the consensus estimate of $4.25. The company earned $4.03 billion during the quarter, compared to analysts' expectations of $3.88 billion. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. The company's revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the company earned $4.25 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan issued an update on its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share guidance of >$16.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 analysts have issued 12-month price objectives for Allergan's stock. Their forecasts range from $144.95 to $203.00. On average, they anticipate Allergan's share price to reach $175.90 in the next twelve months. This suggests that the stock has a possible downside of 8.7%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Press coverage about AGN stock has trended neutral recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Allergan.

Allergan saw a increase in short interest in December. As of December 31st, there was short interest totalling 14,580,000 shares, an increase of 19.2% from the December 15th total of 12,230,000 shares. Based on an average trading volume of 2,220,000 shares, the days-to-cover ratio is currently 6.6 days. Currently, 4.5% of the company's stock are sold short. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Calamos Advisors LLC (0.11%), Metropolis Capital Ltd (0.06%), Advisors Capital Management LLC (0.04%), Nisa Investment Advisors LLC (0.03%), Commerzbank Aktiengesellschaft FI (0.03%) and Tocqueville Asset Management L.P. (0.03%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, United Services Automobile Association, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Neville Rodie & Shaw Inc., State of Alaska Department of Revenue, Bowling Portfolio Management LLC and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Syquant Capital Sas, Calamos Advisors LLC, Metropolis Capital Ltd, Moon Capital Management LLC, Modus Advisors LLC, Legacy Private Trust Co., Zeke Capital Advisors LLC and Tuttle Tactical Management. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $192.68.

Allergan has a market capitalization of $63.25 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]